Literature DB >> 22025342

Atypical fibroxanthoma: clinicopathologic determinants for recurrence and implications for surgical management.

John S Davidson1, Daniel Demsey.   

Abstract

BACKGROUND AND OBJECTIVES: Atypical fibroxanthoma (AFX) is an uncommon skin tumor occurring primarily in the head and neck region of elderly Caucasian males. Treated with local excision, the disease is thought to be fairly benign but can occasionally demonstrate aggressive local recurrence as well as distant metastasis.
METHODS: Seventy-one cases of AFX were reviewed, representing all patients presenting to the Health Sciences Centre of South Eastern Ontario with the diagnosis of AFX in the period 1989-2008. Demographic and pathologic data were obtained from patient charts for analysis.
RESULTS: Mean age at presentation was 76, with a male:female ratio of 4:1. Recurrence occurred in 10 patients after an average period of 7.3 months. Three recurrent lesions went on to distant metastasis, on average 14.3 months after initial presentation. The remaining 60 tumors did not recur. Histologically, tumor extending beyond the dermis into the underlying adipose and muscular tissue had a 29.4% chance of local recurrence and an 11.8% chance of metastasis compared to lesions confined to the dermis only (9.3% and 1.8%).
CONCLUSIONS: While the majority of AFX presentations are benign, there is a real possibility of metastatic spread. Invasion beyond the dermis and a rapid rate of recurrence are suggestive of a more aggressive clinical course.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 22025342     DOI: 10.1002/jso.22128

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Cytolytic activity of the human papillomavirus type 16 E711-20 epitope-specific cytotoxic T lymphocyte is enhanced by heat shock protein 110 in HLA-A*0201 transgenic mice.

Authors:  Zhenzhen Ding; Rongying Ou; Bing Ni; Jun Tang; Yunsheng Xu
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

Review 2.  Recurrent atypical fibroxanthoma of the limbus.

Authors:  Katja Ullrich; Jane Wells; Catriona Brennan; Jamie Craig
Journal:  BMJ Case Rep       Date:  2013-03-15

3.  Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010.

Authors:  Stanislav N Tolkachjov; Adam R Schmitt; John G Muzic; Amy L Weaver; Christian L Baum
Journal:  Dermatol Surg       Date:  2017-01       Impact factor: 3.398

4.  Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions.

Authors:  Stephen Doggett; James Brazil; Marketa Limova; Leah Press; Sidney Smith; Jeremy Peck
Journal:  J Contemp Brachytherapy       Date:  2017-01-25

5.  Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.

Authors:  Christian Koelsche; Damian Stichel; Klaus G Griewank; Daniel Schrimpf; David E Reuss; Melanie Bewerunge-Hudler; Christian Vokuhl; Winand N M Dinjens; Iver Petersen; Michel Mittelbronn; Adrian Cuevas-Bourdier; Rolf Buslei; Stefan M Pfister; Uta Flucke; Gunhild Mechtersheimer; Thomas Mentzel; Andreas von Deimling
Journal:  Clin Sarcoma Res       Date:  2019-02-14

6.  Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma.

Authors:  Doris Helbig
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

7.  Risk factors for local atypical fibroxanthoma recurrence and progression to pleomorphic dermal sarcoma: A meta-analysis of individualized participant data.

Authors:  Mathias Ørholt; Frederik L Aaberg; Kiya Abebe; S Walsh; Randall K Roenigk; Alessandro Venzo; Grethe Schmidt; Helle Klyver; David H Jensen; Mikkel Herly; Peter V Vester-Glowinski
Journal:  J Surg Oncol       Date:  2022-04-19       Impact factor: 2.885

8.  Metastatic pleomorphic dermal sarcoma: an uncommon skin tumour.

Authors:  Georgios Kravvas; David Veitch; Ian Thomas Logan; Conal Martin Perrett
Journal:  An Bras Dermatol       Date:  2018-03       Impact factor: 1.896

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.